Levodopa-Opicapone Regimen for Parkinson's Wearing-Off Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with Parkinson's disease experiencing end-of-dose motor fluctuations or 'wearing-off' symptoms require an optimized dosing regimen to manage motor complications without inducing further complications from excessive levodopa dosing.
Innovation Solution
Administering a single daily dose of opicapone alongside increased frequency of levodopa doses to maintain a total daily dose, such as 5 doses of levodopa per day with a single 50 mg opicapone dose, optimizing the pharmacokinetic profile to reduce fluctuations and improve treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa dose frequency is increased to manage wearing-off, then motor fluctuations are improved, but dyskinesia severity worsens
Solution Approach 1:
A COMT inhibitor is introduced as an intermediary substance that modifies the pharmacokinetics of levodopa. The COMT inhibitor blocks the degradation of levodopa to 3-O-methyldopa, thereby extending levodopa's plasma half-life and reducing peak-to-trough fluctuations without requiring increased levodopa dosing frequency, thus avoiding dyskinesia exacerbation while maintaining motor control reliability
Solution Approach 2:
The plasma elimination half-life of levodopa is changed from approximately 60-90 minutes to a significantly extended duration through COMT inhibition. This parameter change allows for reduced dosing frequency or lower total daily doses while maintaining stable plasma concentrations, thereby improving motor fluctuation control without inducing dyskinesia
2Duration of action of moving object
If levodopa total daily dose is increased to extend coverage, then wearing-off is improved, but motor complications worsen
Solution Approach 1:
The COMT inhibitor acts as a protective intermediary that prevents the formation of inactive metabolites from levodopa. By blocking COMT activity, the inhibitor preserves levodopa's active form in the plasma, extending its effective half-life and coverage duration without requiring dose increases that would lead to motor complications
Solution Approach 2:
The plasma half-life of levodopa is extended from 60-90 minutes to several hours through COMT inhibition. This parameter change allows patients to maintain therapeutic levodopa levels for longer periods without increasing total daily dose, thereby extending coverage duration while avoiding the development of motor complications
3Loss of time
If levodopa is administered more frequently to reduce off-state time, then quality of life is improved, but treatment complexity increases
Solution Approach 1:
The COMT inhibitor simplifies the dosing regimen by extending levodopa's effective half-life, allowing patients to take fewer doses per day while maintaining adequate coverage. This reduces the complexity of managing multiple dosing times and minimizes the risk of missed doses or improper timing, thereby reducing off-state time without increasing regimen complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The regimen stabilizes plasma levodopa levels, reducing fluctuations and extending the plasma half-life, thereby decreasing the time spent in the 'off' state and increasing the 'on' state, thus improving the patient's quality of life and managing motor complications effectively.
Implementation Method 1
Opicapone is a potent and long-acting COMT inhibitor that reduces the degradation of levodopa to the inactive metabolite 3-O-methyldopa
Implementation Method 2
L-DOPA is able to cross the blood-brain barrier, where it is then converted to dopamine by the enzyme dopamine decarboxylase (DDC)
Implementation Method 3
it has become standard clinical practice to co-administer a peripheral DDC inhibitor (DDCI), such as carbidopa or benserazide, which prevents conversion to dopamine in peripheral tissues
Data Source
AI summary
A method of treating Parkinson's disease in a patient who is receiving N doses of levodopa per day to provide a total daily dose of X mg of levodopa and who is starting to experience motor fluctuations or starting to show signs of “wearing-off”, the treatment comprising administering more than N doses of levodopa per day to provide a total daily dose of X mg of levodopa and administering a single daily dose of Y mg of opicapone, wherein X is from 100 to 1000, N is from 2 to 10 and Y is from 25 to 50.